Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Please check regulation status before ordering; additionel fees can apply.
- Synonyms
- 1-(5-fluoropentyl)-N-8-quinolinyl-1H-indole-3-carboxamide
- Correlated keywords
- forensics sciences AM-2201 AM 2201 isomers cannabinoids receptors CBs CB1 CB2 cannabimimetic quinolinyl carboxylate PB-22 BB-22 cannabimimetic 2201am carboxamides ADB-FUBINACA ADBICA designer drugs 8-quinolinol references standards analytical PB22 PB 22 BB22 BB 22 derivatives 5F-THJ 5F THJ 5-fluoro-THJ
- Product Overview:
Several cannabimimetic quinolinyl carboxylates (PB-22 (Item No. 14096) and BB-22 (Item No. 14099)) and cannabimimetic carboxamide derivatives (ADB-FUBINACA (Item No. 14292) and ADBICA (Item No. 14293)) have been identified as designer drugs in illegal products.{23290} AM 2201 8-quinolinyl carboxamide is a derivative of these compounds where 8-quinolinol replaces the naphthalene group of AM2201 (Item No. 10707), resulting in a chemical structure similar to that of 5-fluoro PB-22 (Item No. 14095). The biological actions of AM 2201 8-quinolinyl carboximide are unknown. This product is intended for forensic and research applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.